Drug Profile
Research programme: organ protection therapeutics - KBP Biosciences
Alternative Names: Anti cancer therapeutics - KBP Biosciences; Anti fibrotics - KBP Biosciences; KBP-7018Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator KBP Biosciences
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Idiopathic pulmonary fibrosis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in China (PO) (KBP Biosciences pipeline, April 2023).
- 25 Apr 2023 Discontinued for Cancer in China (PO) (KBP Biosciences pipeline, April 2023).
- 28 Oct 2018 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in China (PO)